Boston Scientific Corporation, a leading global medical technology company, is headquartered in the United States. Founded in 1979, the company has established itself as a key player in the medical device industry, focusing on innovative solutions across various therapeutic areas, including cardiovascular, rhythm management, and urology. With a strong presence in North America, Europe, and Asia-Pacific, Boston Scientific is renowned for its advanced products and services, such as minimally invasive devices and cutting-edge imaging technologies. The company’s commitment to innovation is exemplified by its numerous milestones, including the development of the first drug-eluting stent. Recognised for its market leadership, Boston Scientific continues to push the boundaries of medical technology, enhancing patient outcomes and improving quality of life. Its dedication to research and development positions it as a trusted partner in healthcare worldwide.
How does Boston Scientific's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Boston Scientific's score of 92 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Boston Scientific reported total carbon emissions of approximately 1,743,000,000 kg CO2e, comprising 87,567,000 kg CO2e from Scope 1, 9,854,000 kg CO2e from Scope 2, and a significant 1,663,859,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming for carbon neutrality in its manufacturing and key distribution sites by 2030. This commitment includes a near-term target to reduce absolute Scope 1 and 2 GHG emissions by 46.2% from a 2019 baseline by 2030. Boston Scientific has achieved a notable 68% reduction in Scope 1 and 2 emissions since 2009. Additionally, the company is committed to reducing Scope 3 emissions by 55% per USD value added within the same timeframe. Long-term goals include a 97% reduction in Scope 1 and 2 emissions per USD value added, equivalent to a 90% absolute reduction by 2050, alongside a similar target for Scope 3 emissions. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Boston Scientific's commitment to sustainability and reducing its environmental impact across its operations.
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 
Boston Scientific's Scope 3 emissions, which increased by 28% last year and decreased by approximately 7% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boston Scientific has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
